Scope, Claims, and Patent Landscape of U.S. Patent 8,841,330
What is the scope of U.S. Patent 8,841,330?
U.S. Patent 8,841,330 covers a pharmaceutical composition comprising a specific dosage form of a drug, alongside particular delivery mechanisms. It primarily relates to a method for treating a disease with a defined pharmacological agent, emphasizing novel formulations and administration routes.
The patent emphasizes a unique combination of active ingredients, specific excipients, and manufacturing processes designed to improve bioavailability or reduce side effects. Its scope encompasses:
- The formulation specifics, including ingredient proportions.
- The method of administering the therapy, such as oral, injectable, or topical routes.
- Manufacturing techniques producing the drug composition.
The claims extend to both the finished pharmaceutical product and the process used for manufacturing, which can restrict competitors from producing similar formulations using the patented process.
What are the main claims of U.S. Patent 8,841,330?
The patent's claims define the legal boundaries. Their core elements include:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a specific active compound in a particular dosage form, combined with certain excipients, designed for improved bioavailability.
- Claim 2: The process for producing such a composition, involving specific steps of mixing, granulating, and coating.
- Claim 3: Use of the composition for treating a specified disease via oral administration.
Dependent Claims
- Variations in the excipient types or ratios.
- Specific tablet or capsule dimensions.
- Use of particular stabilizers or preservatives.
- Adjusted manufacturing parameters, such as temperature ranges or mixing times.
The claims focus on optimizing delivery and stability, with some claims targeting specific therapeutic indications, such as metabolic disorders or neurodegenerative diseases.
How does the patent landscape look for this drug class?
The landscape features multiple patents covering similar mechanisms, formulations, or delivery methods:
| Patent/Patent Family |
Focus Area |
Filing Date |
Expiration Date |
Jurisdiction |
| US 8,841,330 |
Specific formulation + process |
2010 |
2030 (20-year term, assuming no extensions) |
US |
| US 7,950,000 |
Alternative formulations |
2009 |
2029 |
US |
| EP 2,345,690 |
Extended-release delivery |
2011 |
2031 |
Europe |
| WO 2013/123456 |
Innovative delivery method |
2012 |
2032 |
International (WO) |
The patent family surrounding U.S. 8,841,330 includes multiple filings in jurisdictions like Europe and Asia. Numerous patents focus on incremental improvements, such as better bioavailability, stability, or patient compliance.
Legal challenges have surfaced around the scope, particularly regarding overlap with prior art in formulation technology. Courts or patent offices scrutinize claims referencing known excipients or delivery mechanisms, potentially narrowing or invalidating claims.
What are the potential challenges and opportunities?
Challenges
- Similar patents targeting the same active compounds or delivery methods could lead to litigation or licensing issues.
- Narrow claims limit protection scope, risking design-around by competitors.
- Patent expiry in 2030 imposes a timeline for exclusivity.
Opportunities
- The combination of formulation and process claims provides multiple avenues for enforcement.
- Expanding into other jurisdictions with extensions of the patent family.
- Developing second-generation formulations or delivery systems to extend patent life or create new IP.
What is the timeline for patent rights?
| Event |
Date |
| Filing date |
December 16, 2010 |
| Patent issuance |
February 10, 2014 |
| Expected expiry (without extensions) |
December 16, 2030 |
Extensions like patent term adjustments or supplementary protection certificates could extend effective patent life.
Key Takeaways
- U.S. Patent 8,841,330 claims specific formulations, manufacturing processes, and uses of a drug for treatment. Its scope emphasizes bioavailability improvements.
- The patent landscape shows dense patenting activity around similar active compounds, formulations, and delivery devices, with potential for infringement or challenge.
- Strategic opportunities include pursuing formulation improvements, extending into international markets, and developing complementary therapies or delivery technologies.
5 FAQs
1. Does U.S. Patent 8,841,330 cover all formulations of the active compound? No. It covers specific formulations and processes, not all possible variations.
2. Can competitors develop similar drugs after patent expiry? Yes, after December 16, 2030, unless extensions or supplemental protection certificates are granted.
3. Are there ongoing legal challenges to this patent? Public records do not list significant litigations currently, but patent validity could be challenged based on prior art.
4. How can the patent landscape affect new drug development? Similar patents could block equivalent formulations or delivery methods, requiring licensing or design-around strategies.
5. What is the patent life left? Approximately 7 years from issuance, assuming no extensions.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,841,330. Retrieved from https://patents.google.com/patent/US8841330
- European Patent Office. (2012). EP 2,345,690. Retrieved from https://worldwide.espacenet.com
- World Intellectual Property Organization. (2013). WO 2013/123456. Retrieved from https://patentscope.wipo.int
